New light on ω-3 polyunsaturated fatty acids and diabetes debate: a population pharmacokinetic-pharmacodynamic modelling and intake threshold study.

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Ling Wang, Xiaomin Huang, Mingyao Sun, Tian Zheng, Luyan Zheng, Xiaolan Lin, Junshan Ruan, Fan Lin
{"title":"New light on ω-3 polyunsaturated fatty acids and diabetes debate: a population pharmacokinetic-pharmacodynamic modelling and intake threshold study.","authors":"Ling Wang, Xiaomin Huang, Mingyao Sun, Tian Zheng, Luyan Zheng, Xiaolan Lin, Junshan Ruan, Fan Lin","doi":"10.1038/s41387-024-00262-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>ω-3 polyunsaturated fatty acids (PUFA) are a key modifiable factor in the intervention of type 2 diabetes, yet recommendations for dietary consumption of ω-3 PUFA in type 2 diabetes remain ambiguous and controversial. Here, we revisit the subject in the light of population pharmacokinetic-pharmacodynamic (PPK-PD) modeling and propose a threshold for intake.</p><p><strong>Research design and methods: </strong>Plasma levels of ω-3 PUFA and glycosylated hemoglobin (HbA<sub>1c</sub>) were measured as pharmacokinetic and pharmacodynamic indicator, respectively. The nonlinear mixed effect analysis was used to construct a PPK-PD model for ω-3 PUFA and to quantify the effects of FADS gene polymorphism, age, liver and kidney function, and other covariables.</p><p><strong>Results: </strong>Data from 161 patients with type 2 diabetes in the community were modeled in a two-compartment model with primary elimination, and HDL was a statistically significant covariate. The simulation results showed that HbA<sub>1c</sub> showed a dose-dependent decrease of ω-3 PUFA plasma level. A daily intake of ω-3 PUFA at 0.4 g was sufficient to achieve an HbA<sub>1c</sub> level of 7% in more than 95% of patients.</p><p><strong>Conclusions: </strong>PPK/PD modeling was proposed as a multilevel analytical framework to quantitatively investigate finer aspects of the complex relationship between ω-3 PUFA and type 2 diabetes on genetic and non-genetic influence factors. The results support a beneficial role for ω-3 PUFA in type 2 diabetes and suggested the intake threshold. This new approach may provide insights into the interaction of the two and an understanding of the context in which changes occur.</p>","PeriodicalId":19339,"journal":{"name":"Nutrition & Diabetes","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10912742/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition & Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41387-024-00262-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: ω-3 polyunsaturated fatty acids (PUFA) are a key modifiable factor in the intervention of type 2 diabetes, yet recommendations for dietary consumption of ω-3 PUFA in type 2 diabetes remain ambiguous and controversial. Here, we revisit the subject in the light of population pharmacokinetic-pharmacodynamic (PPK-PD) modeling and propose a threshold for intake.

Research design and methods: Plasma levels of ω-3 PUFA and glycosylated hemoglobin (HbA1c) were measured as pharmacokinetic and pharmacodynamic indicator, respectively. The nonlinear mixed effect analysis was used to construct a PPK-PD model for ω-3 PUFA and to quantify the effects of FADS gene polymorphism, age, liver and kidney function, and other covariables.

Results: Data from 161 patients with type 2 diabetes in the community were modeled in a two-compartment model with primary elimination, and HDL was a statistically significant covariate. The simulation results showed that HbA1c showed a dose-dependent decrease of ω-3 PUFA plasma level. A daily intake of ω-3 PUFA at 0.4 g was sufficient to achieve an HbA1c level of 7% in more than 95% of patients.

Conclusions: PPK/PD modeling was proposed as a multilevel analytical framework to quantitatively investigate finer aspects of the complex relationship between ω-3 PUFA and type 2 diabetes on genetic and non-genetic influence factors. The results support a beneficial role for ω-3 PUFA in type 2 diabetes and suggested the intake threshold. This new approach may provide insights into the interaction of the two and an understanding of the context in which changes occur.

Abstract Image

ω-3多不饱和脂肪酸与糖尿病之争的新启示:人群药代动力学-药效学模型和摄入阈值研究。
目的:ω-3 多不饱和脂肪酸(PUFA)是干预 2 型糖尿病的一个关键可调节因素,但关于 2 型糖尿病患者膳食中ω-3 多不饱和脂肪酸摄入量的建议仍不明确且存在争议。在此,我们根据群体药代动力学-药效学(PPK-PD)模型重新探讨了这一问题,并提出了摄入量的阈值:研究设计与方法:测量血浆中ω-3 PUFA和糖化血红蛋白(HbA1c)的水平,分别作为药代动力学和药效学指标。采用非线性混合效应分析构建了ω-3 PUFA的PPK-PD模型,并量化了FADS基因多态性、年龄、肝肾功能和其他协变量的影响:将 161 名社区 2 型糖尿病患者的数据建立在一级消除的二室模型中,高密度脂蛋白是一个具有统计学意义的协变量。模拟结果显示,HbA1c随ω-3 PUFA血浆水平的下降而呈剂量依赖性下降。每天摄入 0.4 克 ω-3 PUFA 就足以使 95% 以上的患者 HbA1c 水平达到 7%:PPK/PD模型是一个多层次的分析框架,用于定量研究ω-3 PUFA与2型糖尿病之间的复杂关系,以及遗传和非遗传影响因素。研究结果支持ω-3 PUFA对2型糖尿病的有益作用,并提出了摄入阈值。这一新方法可使人们深入了解两者之间的相互作用,并了解发生变化的背景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nutrition & Diabetes
Nutrition & Diabetes ENDOCRINOLOGY & METABOLISM-NUTRITION & DIETETICS
CiteScore
9.20
自引率
0.00%
发文量
50
审稿时长
>12 weeks
期刊介绍: Nutrition & Diabetes is a peer-reviewed, online, open access journal bringing to the fore outstanding research in the areas of nutrition and chronic disease, including diabetes, from the molecular to the population level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信